Mucosal immunity-stimulating agent, and oral pharmaceutical composition for treating hpv infection
A technology of mucosal immunity and stimulant, which is applied in the directions of drug combination, drug delivery, microorganisms, etc., can solve the problems of not providing HPV vaccine for cervical cancer patients and not developing it.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0224]
[0225] Oral immunization with the LacE7 preparation of mice was carried out according to the method described in K. Adachi et al., Vaccine, 2010, vol.28, pp.2810-2817. At this time, Shiquan Dabu Decoction (hereinafter referred to as "JTT") and Buzhong Yiqi Decoction (hereinafter referred to as "HET") were orally administered to the mice as needed, and further Drug LTB polypeptide or synthetic ceramide (αGalCer).
[0226] >
[0227] LacE7 preparations were produced according to known methods (PooH. et al., Int. J. Immunol., 2006, vol. 119, pp. 1702-1709). Briefly, in Lactobacillus casei for which the inducibility of helper T cell type 1 (Th1 cells) was confirmed, the mutant E7 protein (composed of the amino acid sequence shown in SEQ ID NO: 3 amino acid residues in the Rb binding site of the protein were substituted). The cultured recombinant (LacE7) was killed by heat. LacE7 purified from the culture medium was washed several times with distilled water, dried an...
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com